Oncolytics Biotech announced that pelareorep, an investigational immunotherapy, significantly enhances HPV-16-specific T cell and tumor-infiltrating lymphocyte expansion in anal cancer patients, doubling immune activation after one treatment cycle. Combined with checkpoint inhibitors, pelareorep improved response rates and duration compared to current therapies in second-line or later squamous cell anal cancer. These findings support pelareorep's potential as a backbone immunotherapy for HPV-driven cancers, with plans to pursue strategic partnerships to accelerate development and commercial opportunities across multiple cancer types.
The story on pelareorep's immune response in anal cancer patients is presented here with Health-sector market context from Pluang. For readers following Health stocks, 127 of 150 priced US stocks rose while 19 fell. Notable movers include NUWE at USD 5.25 with a -11.17% change and 100% sell order activity, OSCR at USD 35.45 with a +9.38% change and 84% buy order activity, and HCA at USD 496.00 with a +7.16% change. Data is as of Nov 04, 2026 20:41 WIB.
The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...
No7 Software has enhanced its Anchor Loyalty & Rewards app by integrating Shopify POS, allowing merchants to run a unified loyalty program across online stores and physical shops. Customers now maintain a single points balance, tier status, and refer...
A growing town replaced its inefficient IT request process of spreadsheets and emails with a centralized Microsoft Power Apps hub developed by eSoftware Associates. This hub integrates project intake, risk assessment, and PMO scoring into one platfor...
Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
